Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000882 · ClinicalTrials.gov registry record · Phase 2
STAR Cape+BKM120 MBC With Brain Met
A Phase 2 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02000882 is a Phase 2 study that has completed, run by US Oncology Research. The registered enrollment target is 10 participants.
The verdict
NCT02000882, a Phase 2 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer. Like capecitabine, BMK120 is also effective in crossing the blood brain barrier making it a preferred candidate for its evaluation in patients with metastatic breast cancer (MBC).
Interventions
- DRUG Trastuzumab
- DRUG capecitabine
- DRUG BKM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-05-29 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000882
The ClinicalTrials.gov registry entry for NCT02000882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT02000882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02000882 about?
NCT02000882 is a clinical study titled "STAR Cape+BKM120 MBC With Brain Met". This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer. Like capecitabine, BMK120 is also effective in crossing the blood brain ...
What is the current status of trial NCT02000882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2014-05-29. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT02000882?
The interventions under investigation include: Trastuzumab (DRUG), capecitabine (DRUG), BKM120 (DRUG).
Who is sponsoring clinical trial NCT02000882?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.